CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
gadoxetic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02395991
NCT02395991N/ACompleted
CompareCT.gov

Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI

Seoul National University Hospital·observational·Posted Mar 24, 2015·Updated May 26, 2021

In Brief

An observational study evaluating gadoxetic acid and Magnetic resonance imaging (MRI) for Dyspnea. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA administration by obtaining continuous dynamic T1 weighted image data.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDyspnea
CountriesSouth Korea
CollaboratorsBayer

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartApr 1, 2015
Primary CompletionOct 1, 2016
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.3 years ago

Interventions

gadoxetic aciddrug

standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration

Magnetic resonance imaging (MRI)other

Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases. precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.